Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
International Development
|
Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
|
Regulation, Policies or Program
|
|
Economic Development
|
Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
|
Policies or Program
|
|
Industry
|
Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
|
Policies or Program
|
|
Industry
|
Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process.
|
Policies or Program
|
|
Health
|
National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians.
|
Policies or Program
|
|
Industry
|
Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices.
|
Regulation
|
|
Intellectual Property
|
Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada.
|
Regulation
|
|
Industry
|
Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry.
|
Policies or Program
|
|
International Development
|
Public policy issues related to Health Canada's review of NICE
|
Policies or Program
|
|
International Development
|
Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally.
|
Policies or Program
|
|
Research and Development
|
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada.
|
Policies or Program
|
|
International Trade
|
The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection.
|
Policies or Program
|
|
Science and Technology
|
Through Innovation, Science & Industry discuss opportunities to enhance the Canadian life sciences sector including, biomanufacturing, partnerships, R&D investments.
|
Policies or Program
|
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company’s website at www.astrazeneca.ca.
Gaby Bourbara, President
Address:
1004 Middlegate Road, Suite 5000
Mississauga, ON L4Y 1M4
Canada
Telephone number:
800-565-5877
AstraZeneca Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking